Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

The company’s flagship product, Rezdiffra, has shown strong commercial performance since its FDA approval in March 2024, becoming the first approved therapy for F2-F3 MASH in the U.S. In the ...

Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...